

Uppsala 2024-01-23

## **DBP International AB: Brazilian patent for Temodex / SI-053 is granted**

Double Bond Pharmaceutical International AB (publ) ("DBP" or "The Company", org. No. 556991-6082) has today, January 23<sup>rd</sup> 2024, received information of the approval of a Brazilian patent application concerning the company's front-line product Temodex / SI-053.

Patent approval provides protection for the technology and the product in Brazil until at least 2036.

*"This is an important milestone in the development of SI-053 to get product patented and this is very good news for the company especially now prior starting clinical trials", comments Igor Lokot, CEO of DBP. – "We also have other applications pending for additional important markets."*

**More about Temodex/SI-053:** Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared under the name SI-053 to pass through all the tests and trials required for registration within the EU and globally. **Video presentation:** <https://youtu.be/iweOQPq316o>

*This information is information that Double Bond Pharmaceutical International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above at January 23, 2024*

---

**Full Company Name:** Double Bond Pharmaceutical International AB (publ)

**Corporate identity:** 556991-6082

**Stock short name:** DBP B

**Share ISIN code:** SE0007185525

For more info, contact

Igor Lokot, CEO



Homepage: <http://www.doublebp.com/>

E-mail: [info@doublebp.com](mailto:info@doublebp.com)

Follow us on [LinkedIn](#) and [Twitter](#)!

---

### **Information on Double Bond Pharmaceutical International AB**

DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company's own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. Double Bond Pharmaceutical acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015, and was granted Orphan Drug Designation status by EMA for in July 2016 for this formulation of temozolomide for the treatment of glioma. The formulation is now being further developed for registration in EU and globally and has a working name SI-053 in DBP pipeline.